Pfizer and BioNTech said Wednesday they have reached an agreement to supply the European Union with another 200 million doses of their COVID-19 vaccine.
The US and German companies said in a statement that the doses come on top of the 300 million initially ordered. The EU's executive Commission has an option to request a further 100 million doses.
They said the 200 million doses are expected to be delivered this year, with an estimated 75 million of them in the second quarter.
The Pfizer-BioNTech vaccine was the first of three so far to be approved for use in the EU, which faces criticism for a slow start to its vaccination campaign. The other two approved vaccines are from Moderna and AstraZeneca.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.